Think Positive: Clovis Confident Of CHMP Okay For Rubraca

 
• By Kevin Grogan

The US biotech expects to finally get its PARP inhibitor for ovarian cancer onto the European market in the next few months to compete with rivals AstraZeneca and Tesaro after the CHMP "communicated a positive trend vote" ahead of an opinion being issued next month.

SC1802_Crossed Fingers_351834077_1200.jpg
Fingers crossed: Clovis expects good news from the CHMP in March • Source: Shutterstock

More from Anticancer

More from Therapy Areas